Published in J Clin Invest on December 15, 1996
Effects of Growth Hormone on the Nitric Oxide Pathway | NCT00470002
Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice. Am J Physiol Heart Circ Physiol (2008) 1.55
L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol (1998) 1.39
Hormonal modulation of endothelial NO production. Pflugers Arch (2010) 1.26
Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab (2008) 1.11
The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol (2013) 1.09
Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev (2012) 1.01
Pre-weaning growth hormone treatment reverses hypertension and endothelial dysfunction in adult male offspring of mothers undernourished during pregnancy. PLoS One (2013) 0.93
Growth hormone, prolactin, and sexuality. J Endocrinol Invest (2012) 0.84
GH and the cardiovascular system: an update on a topic at heart. Endocrine (2014) 0.84
The GH/IGF-1 Axis and Heart Failure. Curr Cardiol Rev (2009) 0.84
Short-term administration of growth hormone (GH) lowers blood pressure by activating eNOS/nitric oxide (NO)-pathway in male hypophysectomized (Hx) rats. BMC Physiol (2005) 0.83
The IGF-1 receptor as a therapeutic target to improve endothelial progenitor cell function. Mol Med (2008) 0.83
Non-invasive measurement of the haemodynamic effects of inhaled salbutamol, intravenous L-arginine and sublingual nitroglycerin. Br J Clin Pharmacol (2009) 0.82
Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men. J Clin Endocrinol Metab (2014) 0.82
The prolactin family hormones regulate vascular tone through NO and prostacyclin production in isolated rat aortic rings. Acta Pharmacol Sin (2015) 0.81
Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I. J Clin Endocrinol Metab (2008) 0.80
Potential future options in the pharmacotherapy of female sexual dysfunction. World J Urol (2006) 0.78
Growth hormone therapy influences endothelial function in children with renal failure. Pediatr Nephrol (2004) 0.78
Role of Growth Hormone Deficiency and Treatment in Chronic Kidney Disease. Cardiorenal Med (2011) 0.75
Extracellular water and blood pressure in adults with growth hormone (GH) deficiency: a genotype-phenotype association study. PLoS One (2014) 0.75
The L-arginine-nitric oxide pathway. N Engl J Med (1993) 14.38
Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A (1991) 8.04
Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) (1984) 5.79
Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed) (1984) 5.06
Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev (1989) 3.55
Premature mortality due to cardiovascular disease in hypopituitarism. Lancet (1990) 2.92
Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet (1992) 2.66
The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med (1989) 2.57
Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab (1994) 2.21
Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest (1992) 2.07
Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res (1994) 1.84
Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet (1992) 1.81
Radioimmunoassays for IGFs and IGFBPs. Growth Regul (1994) 1.72
Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet (1989) 1.63
Growth hormone and the heart. Endocr Rev (1994) 1.53
Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ Res (1993) 1.53
Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab (1993) 1.45
Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int (1994) 1.35
Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension (1995) 1.34
Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci U S A (1992) 1.34
Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation (1994) 1.31
Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) (1994) 1.29
L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci (Lond) (1994) 1.14
Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb (1993) 1.14
Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol (1985) (1991) 1.13
Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol (1996) 1.10
Insulin, insulin-like growth factors, and vascular endothelium. Am J Med (1988) 1.10
Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) (1993) 1.09
L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation (1996) 1.05
L-arginine infusion induces hypotension and diuresis/natriuresis with concomitant increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin Exp Pharmacol Physiol (1992) 1.01
Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis (1995) 1.01
Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol (1994) 1.00
Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int (1991) 0.98
Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism (1993) 0.98
Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) (1992) 0.97
Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring. Diabetes (1994) 0.96
Growth hormone in the regulation of hyperlipidemia. Metabolism (1982) 0.96
Studies of hyperlipidemia in the HGH-deficient state. Metabolism (1972) 0.92
Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf) (1994) 0.92
Increased myocardial contractility following growth hormone administration in normal man. An echocardiographic study. Dan Med Bull (1988) 0.91
Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. J Chromatogr B Biomed Appl (1994) 0.91
L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb (1994) 0.88
Effect of subacute administration of human growth hormone on various serum lipid and hormone levels of hypercholesterolemic and normocholesterolemic subjects. Metabolism (1974) 0.88
[Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?]. Klin Wochenschr (1991) 0.85
Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. A review paper. Horm Res (1995) 0.84
Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab (1996) 0.83
Growth hormone, insulin-like growth factor and the kidney. Kidney Int (1995) 0.83
Nitric oxide--biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis (1995) 0.83
Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulates urinary nitrate and cGMP excretion in rats. Cardiovasc Res (1994) 0.81
Insulin-like growth factor-I modulates monocyte adhesion to EAhy 926 endothelial cells. Int J Exp Pathol (1996) 0.81
Determination of cardiac output by echocardiography. J Vet Med Sci (1995) 0.80
Urinary NO3- excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-name in rats. Clin Exp Pharmacol Physiol (1996) 0.80
The effects of native LDL and oxidized LDL on EDRF bioactivity and nitric oxide production in vascular endothelium. J Lab Clin Med (1994) 0.79
Aortic distensibility in growth hormone deficient adults. Lancet (1993) 0.78
Growth hormone therapy in adults: rationales, results, and perspectives. Exp Clin Endocrinol (1994) 0.77
Effects of LDL on intracellular free calcium and nitric oxide-dependent cGMP formation in porcine endothelial cells. Atherosclerosis (1995) 0.77
Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet (1998) 4.92
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation (1998) 3.25
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS (1999) 2.47
[Recommendations and unanswered questions in the diagnosis and treatment of thyroid nodules. Opinion of the Thyroid Section of the German Society for Endocrinology]. Dtsch Med Wochenschr (2005) 2.45
Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation (1997) 2.20
Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene (2005) 2.11
Serum leptin and ghrelin correlate with disease activity in ANCA-associated vasculitis. Rheumatology (Oxford) (2008) 2.11
Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut (2001) 1.97
Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol (1997) 1.83
Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int (2000) 1.79
LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res (2000) 1.76
International multicentre trial protocol to assess the efficacy and safety of tenecteplase during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest: the Thrombolysis in Cardiac Arrest (TROICA) Study. Eur J Clin Invest (2005) 1.64
Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) (2001) 1.59
Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet (1994) 1.53
Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest (2003) 1.49
The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol (2001) 1.46
Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther (2000) 1.44
Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol (Oxf) (2000) 1.35
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33
Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol (1999) 1.32
Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett (2000) 1.29
The cadherin-catenin system: implications for growth and differentiation of endocrine tissues. Endocr Rev (1999) 1.24
Expression of leptin and leptin receptor isoforms in the human stomach. Gut (2000) 1.22
Serum leptin and weight reduction in female obesity. Eur J Endocrinol (1996) 1.20
Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol (2000) 1.17
Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer (2010) 1.15
Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling. Eur J Endocrinol (2005) 1.14
An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol (2000) 1.10
Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res (1999) 1.09
Changes in cardiovascular risk factors and hormones during a comprehensive residential three month kriya yoga training and vegetarian nutrition. Acta Physiol Scand Suppl (1997) 1.09
Prostaglandins and renin release: I. Stimulation of renin release from rabbit renal cortical slices by PGI2. Prostaglandins (1977) 1.06
Cyclosporin in infiltrative eye disease. Lancet (1984) 1.05
Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation (1997) 1.04
Prostaglandins are overproduced by the kidneys and mediate hyperreninemia in Bartter's syndrome. Trans Assoc Am Physicians (1976) 1.02
Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis (1995) 1.01
N(G)-nitro-L-arginine- and indomethacin-resistant endothelium-dependent relaxation in the rabbit renal artery: effect of hypercholesterolemia. Atherosclerosis (1997) 1.01
Pulsatile growth hormone secretion in normal-weight and obese men: differential metabolic regulation during energy restriction. Metabolism (1995) 1.00
Gene expression of differentiation- and dedifferentiation markers in normal and malignant human thyroid tissues. Exp Clin Endocrinol (1992) 1.00
Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol (1999) 1.00
Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab (1997) 0.99
Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins (1976) 0.98
Effects of insulin and glucocorticoids on the leptin system are mediated through free leptin. Clin Endocrinol (Oxf) (2001) 0.98
Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost (2000) 0.96
Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol (1998) 0.96
Hypertrophy and hyperplasia during goitre growth and involution in rats--separate bioeffects of TSH and iodine. Acta Endocrinol (Copenh) (1987) 0.95
Copeptin as a marker for arginine-vasopressin/antidiuretic hormone secretion in the diagnosis of paraneoplastic syndrome of inappropriate ADH secretion. Endocrine (2013) 0.94
Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes (2004) 0.94
UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab (1997) 0.94
Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res (1997) 0.93
Pulse amplitude and frequency modulation of parathyroid hormone in plasma. J Clin Endocrinol Metab (1989) 0.93
Temporal patterns of alpha 1-receptor stimulation regulate amplitude and frequency of calcium transients. Am J Physiol (1993) 0.92
Induction of hyperthyroidism by interferon-alpha-2b. Lancet (1989) 0.92
High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH). Ann Oncol (2011) 0.91
Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. J Chromatogr B Biomed Appl (1994) 0.91
Time series prediction of plasma hormone concentration. Evidence for differences in predictability of parathyroid hormone secretion between osteoporotic patients and normal controls. J Clin Invest (1995) 0.91
Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level. J Clin Psychiatry (1980) 0.90
Circadian and pulsatile thyrotropin secretion in euthyroid man under the influence of thyroid hormone and glucocorticoid administration. J Clin Endocrinol Metab (1987) 0.90
Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol (2001) 0.90
Hypopituitarism in a HIV affected patient. Exp Clin Endocrinol Diabetes (2011) 0.90
Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol (2000) 0.89
Aberrations of chromosomes 5 and 8 as recurrent cytogenetic events in anaplastic carcinoma of the thyroid as detected by fluorescence in situ hybridisation and comparative genomic hybridisation. Virchows Arch (2000) 0.89
Dyslipemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene. J Clin Endocrinol Metab (2001) 0.89
Headache and pituitary disease: a systematic review. Clin Endocrinol (Oxf) (2013) 0.88
Free leptin, bound leptin, and soluble leptin receptor in normal and diabetic pregnancies. J Clin Endocrinol Metab (1999) 0.88
Elevated bound leptin correlates with energy expenditure in cirrhotics. Gastroenterology (2000) 0.88
Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. Clin Nephrol (2004) 0.88
Twenty-four-hour rhythms of plasma catecholamines and their relation to cardiovascular parameters in healthy young men. Eur J Endocrinol (1997) 0.87
Diet-induced obesity alters behavior as well as serum levels of corticosterone in F344 rats. Physiol Behav (2009) 0.87
Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis (1998) 0.87
Identification of novel CBFA1/RUNX2 mutations causing cleidocranial dysplasia. J Inherit Metab Dis (2001) 0.87
Following brain trauma, copeptin, a stable peptide derived from the AVP precusor, does not reflect osmoregulation but correlates with injury severity. Acta Neurochir Suppl (2010) 0.87
Menin mutations in patients with multiple endocrine neoplasia type 1. Eur J Endocrinol (1997) 0.86
Frequency and amplitude enhancement of calcium transients by cyclic AMP in hepatocytes. Biochem J (1991) 0.86
Dietary L-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis (1998) 0.86
Quantitative vapor-phase analysis of prostaglandin F2 in female human urine. Prostaglandins (1973) 0.85
Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin. J Appl Physiol (1985) (1995) 0.85
Functional and morphological changes of the thyroid gland following 5 days of pulsatile TRH stimulation in male rats. J Endocrinol (1995) 0.85
Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab (2011) 0.85
Sex steroids and body composition in men with cystic fibrosis. Eur J Endocrinol (2003) 0.85
Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. Scand J Gastroenterol (2001) 0.85
Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol (2000) 0.85
Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res (2004) 0.85
Immune thyroiditis after transplantation of allogeneic CD34+ selected peripheral blood cells. Bone Marrow Transplant (1997) 0.85
L-arginine stimulates NO-dependent vasodilation in healthy humans--effect of somatostatin pretreatment. J Investig Med (1999) 0.84
Wnts differentially regulate colony growth and differentiation of chondrogenic rat calvaria cells. Biochim Biophys Acta (2001) 0.84
Molecular cloning of a functional promoter of the human plakoglobin gene. Eur J Endocrinol (2001) 0.84
The role of glucocorticoids in the regulation of thyrotropin. Acta Endocrinol (Copenh) (1989) 0.84
Identification of a Wnt/beta-catenin signaling pathway in human thyroid cells. Endocrinology (2001) 0.84
Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. J Clin Endocrinol Metab (1990) 0.84
Display-oriented data system for multiple ion detection with gas chromatography-mass spectrometry in quantifying biomedically important compounds. Anal Chem (1973) 0.84
Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. Clin Pharmacol Ther (2010) 0.83
Coding efficiency and information rates in transmembrane signaling. Biosystems (2000) 0.83
Measurement of intracellular Ca2+ in single aequorin-injected and suspensions of fura-2-loaded ROS 17/2.8 cells and normal human osteoblasts. Effect of parathyroid hormone. Biochem J (1991) 0.83
Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the study of health in Pomerania (SHIP). Exp Clin Endocrinol Diabetes (2009) 0.83